Roche Acquires Spark Therapeutics for Dollars 4.3 Billion

Roche Bids $4.8 Billion for Spark and Its Gene TherapyMore

Roche Bids $4.8 Billion for Spark and Its Gene TherapyMore

With Spark, Roche enters a crowded haemophilia gene therapy market, as other players - Biomarin Pharma, Uniqure NV and Sangamo Therapeutics - also have gene therapies in the works.

Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark Therapeutics common stock, and Spark Therapeutics will file a recommendation statement containing the unanimous recommendation of its board that shareholders tender their shares to Roche. Ltd. grew its holdings in shares of Spark Therapeutics by 103.4% during the fourth quarter. (NASDAQ:ONCE) for 513,140 shs. ONCE underperformed by 41.24% the S&P 500.

According to the Wall Street Journal report revealed yesterday (February 23rd), if not sooner, the takeover deal for Spark Therapeutics Inc would be announced on Monday, at a price tag of roughly $5 billion, however the price could still take a slide, as cited in the Wall Street Journal citing people who wished to remain anonymous.

Total analysts of 10 have positions in Spark Therapeutics (NASDAQ:ONCE) as follows: 7 rated it a "Buy", 0 with "Sell" and 3 with "Hold". Wells Fargo & Com Mn stated it has 0% in Spark Therapeutics, Inc. The positive are 70%. Vanguard Group Inc. owned about 0.07% of Spark Therapeutics worth $154,005,000 as of its most recent SEC filing. On Tuesday, February 19 the stock rating was maintained by Barclays Capital with "Buy". On Wednesday, November 7 the firm earned "Neutral" rating by Wedbush. On Tuesday, February 19 the firm has "Buy" rating by Cowen & Co given. The firm has "Buy" rating given on Wednesday, November 7 by FBR Capital. Finally, B. Riley raised Spark Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the stock from $68.00 to $71.00 in a report on Wednesday, November 7th.

Oscars' best actor award victor pays tribute to his Egpytian roots
Among his reflections after completing " Bohemian Rhapsody " was that no person can really sing like Mercury. "I'm forever in your debt".

Swiss pharma giant Roche Holdings AG Basel ADR (OTC: RHHBY) announced early Monday a deal to buy US -based gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) for $114.50 per share in cash, or a total equity value of $4.8 billion, including about $500 million of net cash expected at close. The company has market cap of $4.28 billion. The Company's products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of it has negative earnings. It now has negative earnings.

Roche's deal for Spark actually looks more expensive than Novartis's AveXis purchase when comparing enterprise value to expected future sales, Sam Fazeli of Bloomberg Intelligence said.

A report by Reuters claims that SPK-8011 is one of the top drug hopefuls of Spark for hemophilia A, which is anticipated to begin Phase 3 trials in 2019. Sign up to our free daily newsletters and get stories sent like this straight to your inbox. - Nasdaq" with publication date: "February 24, 2019.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.